Genomic rearrangements involving genes encoding erythroblast transformation-specific transcription factors are commonly present in prostate cancer. The TMPRSS2-ERG gene fusion that leads to ERG overexpression occurs in B70% of prostate cancers. Implementation of fusion gene detection in pathological practice, however, has been hampered by the lack of reliable ERG antibodies. The objective of this study was first to compare ERG immunohistochemistry using the recently described antibody EPR3864 with ERG mRNA by quantitative PCR and, second, to investigate ERG immunohistochemistry in diagnostic prostate cancer needle biopsies. We analyzed 41 primary prostate adenocarcinomas obtained by radical prostatectomy and 83 consecutive prostate cancer needle biopsies. In the prostatectomy specimens, immunohistochemical ERG expression was highly concordant with the ERG mRNA overexpression (sensitivity 100% and specificity 85%). ERG overexpression was due to TMPRSS2-ERG gene fusion in all cases. ERG protein expression was identified in 51/83 adenocarcinomas (61%) on needle biopsies. ERG expression was more frequent in tumors infiltrating Z2 needle biopsies (Po0.001) or occupying Z50% of a single biopsy (P ¼ 0.018). Expression of ERG also occurred in 11/21 (52%) high-grade prostate intraepithelial neoplasia lesions. In 5/87 (6%) needle biopsies containing benign secretory glands, weak ERG staining was focally observed. In all of these cases, respective glands were adjacent to adenocarcinomas. In conclusion, immunohistochemistry for ERG strongly correlated with ERG mRNA overexpression and was specific for prostate cancer on needle biopsies. Therefore, ERG immunohistochemistry is an important adjunctive tool for pathophysiological studies on ERG gene fusions, and might support the pathological diagnosis of adenocarcinoma in a subset of prostate needle biopsies.
Genomic rearrangements of androgen-regulated, prostate-specific genes to genes encoding erythroblast transformation-specific (ETS) transcription factors characterize the majority of human prostate cancers. Fusion of transmembrane protease, serine 2 (TMPRSS2) to v-ets erythroblastosis virus E26 oncogene homolog (ERG) occurs in 40-70%, representing the most common genetic alteration in prostate cancer. [1] [2] [3] Less frequently, solute carrier family 45, member 3 (SLC45A3) and N-myc downstream regulated 1 (NDRG1) have been reported as ERG fusion partners. [4] [5] [6] Moreover, fusions of ETS variant (ETV) family members ETV1, ETV4 and ETV5 to over 10 different partner genes are present in B10% of tumors. [7] [8] [9] [10] In 20-50% of tumors, no ETS rearrangements can be detected, with a proportion of fusion gene-negative prostate cancers showing overexpression of serine peptidase inhibitor, Kazal type 1 (SPINK1). 11 Since its discovery, several groups have studied the relation of TMPRSS2-ERG, as determined by quantitative PCR (QPCR) or fluorescence in situ hybridization (FISH), with pathological disease parameters, clinical behavior and histological features with varying outcome. [12] [13] [14] [15] [16] [17] [18] [19] Because of its high prevalence, detection of ERG can be of utility in the diagnosis of prostate cancer in daily pathological practice. Application of FISH for this purpose is, however, time consuming and suffers from difficulty in interpretation, especially if only a few atypical glands are present in the tissue sample. Reliable QPCR for routine detection of ERG overexpression needs frozen tissue sections containing a high percentage of prostate cancer. Lack of a reliable ERG antibody has significantly hampered studies on the pathophysiological function of ERG rearrangements in prostate carcinogenesis and on their putative role in tumor progression.
Recently, Park et al 20 compared ERG protein expression by immunohistochemistry, using antibody EPR3864, with ERG rearrangement by FISH in prostate cancer paraffin-embedded tissues. In the current study, we correlated ERG immunohistochemistry with ERG mRNA overexpression caused by gene fusion in primary prostate cancer obtained by radical prostatectomy. Moreover, we applied ERG immunohistochemistry in diagnostic needle biopsies to investigate its utility in pathological practice. The characterization of an antibody specific for ERG genomic rearrangements will highly facilitate studies on gene fusion in prostate carcinogenesis and tumor progression, and might support the pathological diagnosis of adenocarcinoma in a subset of prostate needle biopsies.
Materials and methods

Clinical Samples
For molecular analysis of ERG expression, we included 41 patients treated by radical prostatectomy for prostate cancer in Erasmus Medical Center between 1985 and 2001. None of the patients had undergone radiation or hormonal therapy before surgery. Immediately after arrival at the Pathology department, small samples from the putative tumor area were dissected and freshly frozen in liquid nitrogen. All frozen tissues were stained by hematoxylin/eosin and the percentage of malignant cells was semiquantitatively estimated; in this study, only specimens containing at least 70% tumor cells were included. After formalin fixation, prostatectomy specimens were entirely embedded for diagnostic pathological evaluation, at which the Gleason score, pT stage (WHO 2004) and surgical margin status were routinely determined. We correlated genomic ERG expression as assessed by QPCR on the fresh-frozen sample, with ERG immunohistochemical expression of the paraffin slide containing the largest tumor volume of the same patient. Owing to the retrospective nature of this study, we were unable to determine the topographic relation between the area of which the frozen sample was derived and the paraffin block containing the largest tumor volume.
For 
QPCR
RNA from prostatectomy samples was isolated using RNA-Bee (Campro Scientific, Berlin, Germany). Total RNA was reverse transcribed using M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA) and an oligo dT12 primer. QPCR reactions were performed in Power SYBR Green PCR Master Mix (25 ml), containing 0.33 mM forward and reverse primer in an ABI Prism 7700 Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA). Amplified products were quantified relative to hydroxymethylbilane synthase (HMBS; formerly PBGD). Sequences of the primers used are summarized in Table 1 . To exclude artifacts caused by the The intensity of ERG immunohistochemical expression was scored as negative (0; no staining), weak (1 þ ; only visible at high magnification), moderate (2 þ ; visible at low magnification) and strong (3 þ ; striking at low magnification). Nuclear reactivity of the antibody in endothelial cells was used as internal control for the staining procedure. 20 In case of staining heterogeneity, the highest level was used for statistical analysis.
Statistical Analysis
Associations between expression of ERG mRNA and ERG protein expression in surgical specimens were evaluated by the Pearson's w 2 -test or the MannWhitney U-test. Immunohistochemical expression of ERG in needle biopsies was correlated with age, PSA, Gleason score, number of positive biopsies and maximum percentage of tumor infiltration, using Students' t-test and Pearson's w 2 -test. Statistical analyses were performed using the Statistical Package for Social Sciences, version 17.0 (SPSS, Chicago, IL, USA), with a significance level of 0.05 (twotailed probability).
Results
Correlation of ERG Immunohistochemistry with ERG Gene Fusions
To validate the properties of the ERG antibody, we first compared immunohistochemical staining with ERG mRNA expression in archival primary prostate cancers for which both tumor RNA and paraffin tissue was available (N ¼ 41). The mean age of the prostatectomy patients was 61.9 years (range 49.1-72.8 years). The Gleason score was 6 in 20 (49%), 7 in 13 (32%) and Z8 in 8 (19%) cases, respectively. Fourteen (34%) tumors were organ confined (pT2), and 27 (66%) cases showed extra-prostatic expansion (pT3/4). Surgical margins were positive in 19 (46%) cases. The clinicopathological characteristics of the prostate cancers at prostatectomy and their immunohistochemical ERG expression are summarized in Table 2 . ERG mRNA overexpression was detected in 28 (68%) samples. Of the 13 (32%) Figure 1 ). 19 To exclude artifacts induced by the housekeeping gene HMBS, we also carried out QPCR for GAPDH as a reference, which resulted in an identical selection of ERG-positive cases. The median value of ERG/GAPDH in ERG-positive cases was 28.3 (range 10.5-59.2) as compared with 1.3 (0.3-4.7) in negative tumors.
As shown in Table 4 , prostate cancer with strong immunohistochemical ERG expression (3 þ ) had a significantly higher relative ERG transcript level than tumors with combined weak (1 þ ) and moder- 21 The patients' mean age was 68.2 years (range 39.7-79.2 years). The median PSA level was 6.7 ng/ml (range 0.8-745 ng/ml). Gleason score on needle biopsy was 6 in 48 (58%), 7 in 22 (27%) and Z8 in 13 (15%) tumors. ERG protein expression was identified in 51 adenocarcinomas (61%). Expression of ERG was strong (3 þ ) in 37 (45%), moderate in 8 (10%), weak in 6 (7%) and negative in 32 (38%) tumors (Figure 3) . Immunohistochemical ERG expression was not related to age, PSA level or Gleason score at biopsy, as shown in Table 5 . For analysis of ERG expression in relation to tumor burden, we excluded all patients containing multiple biopsy specimens in one container (see Materials and methods). ERG expression was identified more frequently if Z2 biopsies were infiltrated with adenocarcinoma (Pearson's w 2 , Po0.001) and if Z50% of the biopsy specimen was affected (P ¼ 0.018). This indicates that the sensitivity of ERG protein expression is highest in cases with more abundant tumor infiltration. In fact, when we analyzed ERG expression in the subgroup of patients with one positive needle biopsy infiltrated with r25% of tumor, which represents the most relevant cases for adjuvant immunohistochemical staining (N ¼ 22), seven tumors (32%) were positive.
In the current analysis, we scored ERG immunohistochemistry 'positive' if expression occurred in the whole tumor or in any area of the tumor. Expression heterogeneity was, however, observed within the same needle biopsy or between multiple biopsies included in one container. In 2 of 70 (3%) prostate cancer foci, positive and negative ERG immunohistochemistry occurred within the same needle biopsy, whereas in 2/13 cases (15%), heterogeneity occurred in different needle biopsies included within the same container.
Nuclear antibody reactivity in endothelial cells served as internal control for an adequate immunohistochemical staining procedure. As the ERG antibody is reported to show cross-reactivity with FLI1, we studied FLI1 expression in a set of needle biopsies with ERG-expressing adenocarcinoma. In these cases, weak FLI1 expression was observed in endothelial cells, but prostate adenocarcinoma was negative. Although staining by the ERG antibody of endothelial cells might therefore be, partially, due to cross-reactivity with FLI1, its reactivity in these cells demonstrates the effectiveness of immunohistochemical technique (Figure 4 ).
High-Grade Prostate Intraepithelial Neoplasia
In the series analyzed, a total of 21 needle biopsies contained high-grade prostate intraepithelial neoplasia. Expression of ERG was detected in 11 cases (52%). In all these cases, ERG expression occurred in luminal epithelial cells within the same gland. ERG expression in prostate intraepithelial neoplasia was highly concordant with its expression in adjacent adenocarcinoma (Pearson's w 2 , Po0.001). Of the 19 cases in which prostate intraepithelial neoplasia and adenocarcinoma were present in the same slide, both were positive (N ¼ 10) or negative (N ¼ 8) for ERG; in one case, adenocarcinoma was positive and adjacent prostate intraepithelial neoplasia negative. In two cases, prostate intraepithelial neoplasia was present without residual adenocarcinoma, of which one was positive and one negative for ERG expression (Figure 5a and b) .
Benign Prostate Glands
A total of 87 needle biopsies contained benign secretory glands, which were negative for ERG expression in 82 cases (94%). In five biopsies (6%), focal and weak (1 þ ) ERG expression was detected in histologically benign glands (Figure 5c ). Immunohistochemical ERG expression was not detected in any of the 40 needle biopsies with atrophic glands. The morphologically normal glands that demonstrated weak ERG expression were all located adjacent to or in between malignant glands. We did not encounter any case with ERG expression in benign glands spatially distant from malignant glands. For ERG expression analyses with regard to number of positive needle biopsies and maximum tumor percentage per needle biopsy (*), only cases from Erasmus Medical Center (N ¼ 70) were included. If multiple categories were present, the most significant association was depicted. If needle biopsies containing adenocarcinoma and benign prostate glands were both included, the sensitivity of ERG expression was 61%, specificity 94%, positive predictive value 92% and negative predictive value 72%.
Discussion
Overexpression of ERG fusion transcripts have been detected in B70% of primary prostate cancer. 1, 12, 15, 17, 19, [22] [23] [24] [25] [26] [27] Therefore, it is an important functional tumor marker. TMPRSS2-ERG fusion has been associated with some histological features i.c. (in casu) blue-tinged mucin, cribriform growth, intraductal spread, macronucleoli and signet-ring cells, particularly if more than one of these features were present. 18 ERG gene rearrangements seem to occur less frequently in pure ductal or mixed acinarductal prostate cancer, as compared with conventional acinar tumors. 28 Recently, a rabbit anti-ERG monoclonal antibody was described showing excellent concordance of positive ERG immunohistochemistry with presence of ERG fusion, as detected by FISH, irrespective of the ERG fusion partner. 20 In concordance with these recent findings, we demonstrated in the present study that the ERG protein expression strongly correlated with ERG mRNA overexpression in primary prostate cancer. Moreover, we found that the tumors with highest ERG mRNA overexpression showed strongest ERG immunohistochemistry. In only two cases, ERG protein expression was detected in the absence of ERG mRNA overexpression. Because RNA was isolated from a different tumor section than the tissue slides used for immunohistochemistry, this apparent discrepancy could be explained by intra/ intertumoral heterogeneity of genomic rearrangements, as has been reported in about a quarter of prostate cancer cases. 29, 30 Alternatively, false-positive expression could be due to cross-reactivity of the EPR3864 antibody with the ERG-related ETS protein FLI1, as has been communicated by the manufacturer, although FLI1 mRNA expression was low in all samples analyzed (data not shown). The high sensitivity of ERG protein expression for prostate cancer, as independently found in both studies, indicates that ERG immunohistochemistry could be an adjunctive tool for diagnosing prostate cancer on needle biopsies.
Although the histological diagnosis of prostate cancer is usually straightforward, immunohistochemistry can be applied in the evaluation of difficult cases. Visualization of basal cells using antibodies targeting cytoplasmic basal, high-molecular-weight keratins or nuclear p63 is the traditional and most helpful tool supporting or rejecting prostate cancer diagnosis. Moreover, enhanced cytoplasmic expression of alpha-methylacyl CoAracemase (AMACR) is more common in prostate cancer than in benign glands. Nevertheless, various problems might occur in the interpretation of immunohistochemistry in atypical glandular foci on needle biopsies. 31, 32 For instance, partial atrophy on needle biopsy has an immunophenotype identical to adenocarcinoma in 24% of cases. 31, 33 Atypical adenomatous hyperplasia/adenosis, benign prostate tissue and crowding of secretory glands demonstrate AMACR expression in 17, 21 and 64% of cases, respectively. 31, 34, 35 On the other hand, conventional prostate cancer is negative for AMACR in B 20%, whereas its pseudohyperplastic and foamy gland variants do not reveal expression in 30-40%. 36, 37 Ultimately, aberrant expression of high-molecular-weight keratins in prostate cancer has been reported in rare cases. [38] [39] [40] Therefore, there is an ongoing need for the discovery and clinical implementation of novel biomarkers that can support or reject prostate cancer diagnosis in difficult cases.
In this study, we investigated ERG protein expression in prostate cancer on needle biopsies, which clinically represent the most relevant tissue specimens for implementation of novel biomarkers. Overall expression of ERG occurred in 61% of adenocarcinomas with 94% specificity, indicating that its expression strongly favors a diagnosis of malignancy in difficult cases. The majority of highgrade prostate intraepithelial neoplasias adjacent to ERG-positive adenocarcinoma were also ERG positive. ERG protein expression was only focally and weakly expressed in histologically benign glands. These benign glands were all adjacent to malignant glands.
Immunohistochemical ERG expression was more prevalent in prostate intraepithelial neoplasia than expected, based on previous rearrangement studies by FISH that showed ERG overexpression ranging from 0-17%. 1, 13, 29, 30, 41 This discordance might be caused by underestimation of ERG rearrangements, as the specific pathological features of prostate intraepithelial neoplasia can be appreciated less well by FISH. The high frequency of ERG expression in high-grade intraepithelial neoplasia does not support the hypothesis that ERG overexpression is involved in the transition of prostate intraepithelial neoplasia to adenocarcinoma. 42 In fact, it would support a hypothesis that ERG is instrumental in the formation of high-grade intraepithelial neoplasia from normal prostate epithelium. This is also suggested by the weak ERG expression in about 6% of benign secretory glands that did not fulfill all histopathological criteria for high-grade prostate intraepithelial neoplasia and were adjacent to adenocarcinoma. In concordance with the sporadic occurrence of ERG rearrangements in histologically benign glands, our results support the theory that early molecular aberrations precede pathologically recognizable preneoplasia. 43 Some important points for clinical practice have to be taken into account in interpreting our results. First, ERG was evaluated in needle biopsies containing both adenocarcinomas and benign glands, and not in an independent set of actual benign prostate biopsies. This might have caused a bias in the analysis of ERG specificity in non-malignant tissues. Nevertheless, the absence of ERG expression in benign glands distant from adenocarcinoma within the same biopsy and in multiple benign biopsies concomitantly present within the same container implicates that benign glands indeed only sporadically express ERG protein. Second, the present study indicated that ERG staining is less frequent in single small foci of adenocarcinoma, being positive in one-third of cases with tumor infiltration in r25% of a single needle biopsy. Therefore, it remains the question to what extend ERG immunohistochemistry is complementary to already available antibodies in diagnostic classification of small atypical glandular lesions. The lower percentage of small tumors staining for ERG as compared with more voluminous cancers might partially be explained by the methodology used in the current study. If ERG expression was detected in a heterogeneously staining prostate cancer, this case was labeled as positive. Interestingly, one could also speculate that absence of ERG protein expression is a marker for indolent disease, based on its less frequent presence in small tumors, as has also been suggested by others. 12, 14, 44, 45 The observation that such relation was not reflected by an association between ERG expression and pathological parameters at prostatectomy might be explained by a selection bias of relatively more aggressive tumors in the latter group. As only frozen specimens containing at least 70% tumor tissue were selected, minute, possibly indolent, tumors were not included in the prostatectomy series. However, other explanations cannot be excluded.
In conclusion, ERG protein expression as detected by immunohistochemistry with the ERG3864 antibody is highly concordant with ERG mRNA expression in primary prostate cancer. Moreover, nuclear ERG expression was identified in 61% of adenocarcinomas on diagnostic needle biopsies. ERG expression is also present in about half of the high-grade prostate intraepithelial neoplasia lesions, but it is only rarely found in isolated benign secretory glands. Therefore, ERG immunohistochemistry highly facilitates future studies on the role of ERG overexpression due to gene fusion in clinical prostate cancer.
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